CS060380 / Cascade Pharma - LARVOL DELTA

Trial of CS060380 Tablets for Non-alcoholic Steatohepatitis (NASH) (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: Cascade Pharmaceuticals, Inc | Not yet recruiting ➔ Recruiting

Enrollment open • Hepatology • Metabolic Dysfunction-Associated Steatohepatitis • APOB

Trial of CS060380 Tablets for Non-alcoholic Steatohepatitis (NASH) (clinicaltrials.gov) - P2 | N=60 | Not yet recruiting | Sponsor: Cascade Pharmaceuticals, Inc

New P2 trial • Hepatology • Metabolic Dysfunction-Associated Steatohepatitis • APOB

Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS060380 in Healthy and Elevated LDL-C Subjects (clinicaltrials.gov) - P1 | N=104 | Completed | Sponsor: Cascade Pharmaceuticals, Inc | Active, not recruiting ➔ Completed

Trial completion • Metabolic Dysfunction-Associated Steatohepatitis

Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS060380 in Healthy and Elevated LDL-C Subjects (clinicaltrials.gov) - P1 | N=104 | Active, not recruiting | Sponsor: Cascade Pharmaceuticals, Inc | Recruiting ➔ Active, not recruiting

Enrollment closed • Metabolic Dysfunction-Associated Steatohepatitis

Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS060380 in Healthy and Elevated LDL-C Subjects (clinicaltrials.gov) - P1 | N=80 | Recruiting | Sponsor: Cascade Pharmaceuticals, Inc | Not yet recruiting ➔ Recruiting

Enrollment open • Metabolic Dysfunction-Associated Steatohepatitis